M A Konstam

Summary

Affiliation: Rhode Island Hospital
Country: USA

Publications

  1. ncbi request reprint Current perspective on the cardiovascular effects of coxibs
    Marvin A Konstam
    Tufts University School of Medicine and the New England Medical Center, Boston, MA 02111, USA
    Cleve Clin J Med 69:SI47-52. 2002
  2. ncbi request reprint Improving clinical outcomes with drug treatment in heart failure: what have trials taught?
    Marvin A Konstam
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 91:9D-14D. 2003
  3. ncbi request reprint Contemporary medical options for treating patients with heart failure
    Marvin A Konstam
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center, and Tufts University School of Medicine, Boston, Mass 02111, USA
    Circulation 105:2244-6. 2002
  4. ncbi request reprint Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
    M A Konstam
    Division of Cardiology, New England Medical Center, Boston, Massachusetts, USA
    Circulation 104:2280-8. 2001
  5. ncbi request reprint Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy
    M A Konstam
    Tufts University, New England Medical Center, Boston, MA 02111, USA
    Am Heart J 139:1081-7. 2000
  6. ncbi request reprint Gender-specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor
    Paul Bridgman
    Molecular Cardiology Research Institute, Tufts New England Medical Center, Box 80, 750 Washington St, Boston, MA 02111, USA
    Am J Physiol Heart Circ Physiol 289:H586-92. 2005
  7. ncbi request reprint Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure
    J E Udelson
    Division of Cardiology, New England Medical Center Hospitals Tufts University School of Medicine, Boston, Massachusetts, USA
    Circulation 104:2417-23. 2001
  8. ncbi request reprint Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse
    Richard D Patten
    Molecular Cardiology Research Institute, New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Clin Sci (Lond) 104:109-18. 2003
  9. ncbi request reprint New concepts in post-infarction ventricular remodeling
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Rev Cardiovasc Med 4:S3-12. 2003
  10. ncbi request reprint Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II
    B Pitt
    Division of Cardiology, University of Michigan School of Medicine, Ann Arbor 48109 0366, USA
    Lancet 355:1582-7. 2000

Detail Information

Publications70

  1. ncbi request reprint Current perspective on the cardiovascular effects of coxibs
    Marvin A Konstam
    Tufts University School of Medicine and the New England Medical Center, Boston, MA 02111, USA
    Cleve Clin J Med 69:SI47-52. 2002
    ..Additional placebo-controlled data, from patients at both high and low risk for cardiovascular events, are warranted to clarify the cardiovascular effects of this class of agents...
  2. ncbi request reprint Improving clinical outcomes with drug treatment in heart failure: what have trials taught?
    Marvin A Konstam
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 91:9D-14D. 2003
    ..Clinical trials have provided significant treatment advances; ongoing and future trials will demonstrate the degree to which we can improve on what we have achieved to date with pharmacologic treatments...
  3. ncbi request reprint Contemporary medical options for treating patients with heart failure
    Marvin A Konstam
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center, and Tufts University School of Medicine, Boston, Mass 02111, USA
    Circulation 105:2244-6. 2002
  4. ncbi request reprint Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
    M A Konstam
    Division of Cardiology, New England Medical Center, Boston, Massachusetts, USA
    Circulation 104:2280-8. 2001
    ..A combined analysis of individual patient data was undertaken to determine whether there was an excess of CV thrombotic events in patients treated with rofecoxib compared with those treated with placebo or nonselective NSAIDs...
  5. ncbi request reprint Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy
    M A Konstam
    Tufts University, New England Medical Center, Boston, MA 02111, USA
    Am Heart J 139:1081-7. 2000
    ....
  6. ncbi request reprint Gender-specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor
    Paul Bridgman
    Molecular Cardiology Research Institute, Tufts New England Medical Center, Box 80, 750 Washington St, Boston, MA 02111, USA
    Am J Physiol Heart Circ Physiol 289:H586-92. 2005
    ..Further work is necessary to explore the potential mechanisms underlying these gender-based differences...
  7. ncbi request reprint Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure
    J E Udelson
    Division of Cardiology, New England Medical Center Hospitals Tufts University School of Medicine, Boston, Massachusetts, USA
    Circulation 104:2417-23. 2001
    ..Inhibiting the action of vasopressin may be beneficial in patients with heart failure...
  8. ncbi request reprint Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse
    Richard D Patten
    Molecular Cardiology Research Institute, New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Clin Sci (Lond) 104:109-18. 2003
    ..These results serve as an important basis for planned investigations to evaluate the anti-remodelling effects of these agents on mice in which genetic manipulations are used to disrupt components of the Ang II signalling system...
  9. ncbi request reprint New concepts in post-infarction ventricular remodeling
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Rev Cardiovasc Med 4:S3-12. 2003
    ..It is also demonstrated that drug therapies that slow or reverse the remodeling process appear to have favorable natural history effects in the short term as well as during long-term therapy...
  10. ncbi request reprint Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II
    B Pitt
    Division of Cardiology, University of Michigan School of Medicine, Ann Arbor 48109 0366, USA
    Lancet 355:1582-7. 2000
    ..We did the ELITE II Losartan Heart Failure Survival Study to confirm whether losartan is superior to captopril in improving survival and is better tolerated...
  11. ncbi request reprint Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 297:1332-43. 2007
    ..Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition...
  12. ncbi request reprint Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
    J Card Fail 8:S465-71. 2002
    ..After any insult to the left ventricle resulting in diminished systolic performance and stroke volume, a series of histopathologic changes in the myocardium and structural changes in the LV chamber occurs over time...
  13. ncbi request reprint Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction
    A Al-Ahmad
    Division of Cardiology, Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 38:955-62. 2001
    ..CONCLUSIONS: Decreased kidney function and anemia are risk factors for all-cause mortality in patients with LV dysfunction, especially when both are present. These relationships need to be confirmed in additional studies...
  14. ncbi request reprint Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure
    Olaf Hedrich
    Tufts New England Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    Heart Fail Clin 1:103-27. 2005
  15. ncbi request reprint Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, Mass, USA
    JAMA 297:1319-31. 2007
    ..Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure...
  16. ncbi request reprint Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 49:2151-9. 2007
    ..This study sought to examine the effects of vasopressin V2 receptor antagonism with tolvaptan on the changes in left ventricular (LV) volumes over time...
  17. ncbi request reprint Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis
    John A TenBrook
    Division of Clinical Decision Making, Informatics, and Telemedicine, Department of Medicine, Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    J Allergy Clin Immunol 113:977-82. 2004
    ..Beta-blocker therapy postmyocardial infarction is generally recommended because it reduces mortality. However, beta-blockers may increase anaphylaxis mortality in the growing population of patients with peanut-induced anaphylaxis...
  18. ncbi request reprint Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II)
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, MA 02111, USA
    Am Heart J 150:123-31. 2005
    ..We compared effects of losartan to captopril on mortality, morbidity, and functional status for patients in the ELITE II study...
  19. ncbi request reprint Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL, USA
    J Card Fail 11:260-9. 2005
    ....
  20. ncbi request reprint Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial
    Carey Kimmelstiel
    Division of Cardiology, Tufts New England Medical Center, and Tufts University School of Medicine, Boston, Mass 02111, USA
    Circulation 110:1450-5. 2004
    ..Most of these studies are limited by small sample size; absence of concurrent, randomized controls; limited follow-up; restriction to urban academic centers; and low baseline use of effective medications...
  21. ncbi request reprint Prevention and reversal of left ventricular remodeling: summation
    Marvin A Konstam
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Card Fail 8:S506-11. 2002
  22. ncbi request reprint Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials
    Inder S Anand
    Division of Cardiology, University of Minnesota Medical School and Veterans Administration Medical Center, Minneapolis, MN 55417, USA
    J Card Fail 8:S452-64. 2002
    ..Thus, to study the process of remodeling in practice and in clinical trials, we have relied on assessments and measurements derived from cardiac imaging tests...
  23. ncbi request reprint Recent advances in the treatment of heart failure
    Ayan R Patel
    Division of Cardiology, New England Medical Center and Tufts University, Boston, Massachusetts 02111, USA
    Circ J 66:117-21. 2002
    ..As the importance of neurohormonal activation in the progression of heart failure becomes increasingly apparent, new therapeutic strategies targeting these neurohormonal systems are being investigated...
  24. ncbi request reprint Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction
    J E Udelson
    Division of Cardiology, Department of Medicine, New England Medical Center, Boston, MA 02111, USA
    Am Heart J 139:503-10. 2000
    ....
  25. ncbi request reprint The economic effect of a tertiary hospital-based heart failure program
    Douglas Gregory
    Cardiovascular Clinical Studies and Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:660-6. 2005
    ..This study was designed to determine the economic effect of a tertiary heart failure (HF) program at an academic medical center...
  26. ncbi request reprint Fatty infiltration of right ventricle (adipositas cordis): an unrecognized cause of early graft failure after cardiac transplantation
    Rajan Krishnamani
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center, Boston, MA 02111, USA
    J Heart Lung Transplant 24:1143-5. 2005
    ..If the diagnosis of fatty infiltration is suspected at time of donor harvest, the relative risks and benefits of proceeding with transplantation should be carefully assessed...
  27. ncbi request reprint Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure
    Marvin A Konstam
    Tufts New England Medical Center, Tufts University, Boston, MA, USA
    Circulation 112:3107-14. 2005
    ....
  28. doi request reprint Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor
    Marvin A Konstam
    Tufts Medical Center, Boston, MA 02111, USA
    Eur J Heart Fail 10:899-906. 2008
    ....
  29. doi request reprint Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial
    James E Udelson
    Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 52:1540-5. 2008
    ..This study sought to assess the acute hemodynamic effect of vasopressin V(2) receptor antagonism...
  30. doi request reprint Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment
    James D Flaherty
    Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    J Am Coll Cardiol 53:254-63. 2009
    ..Prospective studies of the assessment and treatment of CAD in patients with AHFS are urgently needed...
  31. doi request reprint The effect of ventricular assist devices on post-transplant mortality an analysis of the United network for organ sharing thoracic registry
    Vishnu Patlolla
    Department of Medicine, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    J Am Coll Cardiol 53:264-71. 2009
    ..This study sought to determine the relationship between pre-transplant ventricular assist device (VAD) support and mortality after heart transplantation...
  32. doi request reprint Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial
    John E A Blair
    Division of Cardiology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair, Suite 600, Chicago, IL 60611, USA
    Eur Heart J 30:1666-73. 2009
    ..We explore the relationship between change in BW after hospitalization for worsening HF and risk for repeat hospitalization and mortality in the EVEREST trial...
  33. doi request reprint Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction
    James E Udelson
    Tufts Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Circ Heart Fail 3:347-53. 2010
    ..Few data are available on effects of aldosterone antagonism in patients with mild-to-moderate HF...
  34. doi request reprint Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach
    Daniel G Kramer
    Division of Cardiology and the CardioVascular Center, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 56:392-406. 2010
    ..The purpose of this study was to quantitatively assess the relationship between therapy-induced changes in left ventricular (LV) remodeling and longer-term outcomes in patients with left ventricular dysfunction (LVD)...
  35. ncbi request reprint Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction
    Douglas D Gregory
    Division of Clinical Decision Making, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Cardiol 92:1300-5. 2003
    ....
  36. ncbi request reprint Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development
    Marvin A Konstam
    Division of Cardiology, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Mass, USA
    Circulation 109:143-5. 2004
  37. ncbi request reprint Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction
    Alawi A Alsheikh-Ali
    Tufts New England Medical Center, Department of Medicine, Division of Cardiolgy, Boston, Mass, USA
    Am Heart J 147:1061-5. 2004
    ..We sought to determine whether enalapril treatment reduced hospitalizations with atrial tachyarrhythmias in patients with LV dysfunction...
  38. ncbi request reprint Reversal of left ventricular remodeling by pericardial tamponade
    Prem Soman
    Division of Cardiology, Tufts New England Medical Center, Boston, MA 02451, USA
    J Card Fail 11:131-3. 2005
  39. doi request reprint Influence of donor cocaine use on outcome after cardiac transplantation: analysis of the United Network for Organ Sharing Thoracic Registry
    Andreas Brieke
    Division of Cardiology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado 80045, USA
    J Heart Lung Transplant 27:1350-2. 2008
    ....
  40. ncbi request reprint Aligning quality and payment for heart failure care: defining the challenges
    Edward P Havranek
    Division of Cardiology, Department of Medicine, Denver Health Medical Center and University of Colorado HSC, Denver, Colorado 80204 4507, USA
    J Card Fail 9:251-4. 2003
    ..This article describes each of these challenges in turn...
  41. ncbi request reprint Peripheral vascular endothelial function correlates with exercise capacity in cardiac transplant recipients
    Ayan R Patel
    Division of Cardiology Department of Medicine, Molecular Cardiology Research Institute, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Am J Cardiol 91:897-9. 2003
  42. doi request reprint Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
    Marvin A Konstam
    Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA
    Lancet 374:1840-8. 2009
    ..We compared the effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure...
  43. ncbi request reprint Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart
    Richard D Patten
    Molecular Cardiology Research Institute, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 45:1419-24. 2005
    ..We examined the effect of mechanical unloading with ventricular assist device (VAD) therapy on myocardial inducible nitric oxide synthase (iNOS) expression and cardiomyocyte apoptosis in patients with end-stage heart failure (HF)...
  44. doi request reprint A multicenter randomized controlled evaluation of automated home monitoring and telephonic disease management in patients recently hospitalized for congestive heart failure: the SPAN-CHF II trial
    Andrew Weintraub
    Division of Cardiology, Tufts Medical Center, Boston, MA, USA
    J Card Fail 16:285-92. 2010
    ..The AHM system measured and transmitted body weight, blood pressure, and heart rate data as well as subjective patient self-assessments via a standard telephone line to a central server...
  45. ncbi request reprint Heart failure training: a call for an integrative, patient-focused approach to an emerging cardiology subspecialty
    Marvin A Konstam
    Division of Cardiology, Department of Medicine, Tufts New England Medical Center, 750 Washington Street, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 44:1361-2. 2004
    ....
  46. doi request reprint Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia
    John J Finley
    Division of Cardiology and Department of Medicine, Tufts Medical Center, Boston, Mass 02111, USA
    Circulation 118:410-21. 2008
  47. doi request reprint Emerging ventricular assist devices for long-term cardiac support
    Rajan Krishnamani
    The Cardiovascular Center, Tufts Medical Center, Boston, MA 02111, USA
    Nat Rev Cardiol 7:71-6. 2010
    ..These devices are at various stages of development and clinical investigation. One or more of these newer devices is likely to emerge as an important development in the treatment of patients with advanced heart failure...
  48. ncbi request reprint Hospital cost effect of a heart failure disease management program: the Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) trial
    Douglas Gregory
    Cardiovascular Clinical Studies, Boston, MA 02111, USA
    Am Heart J 151:1013-8. 2006
    ..Determine the effect on hospitalization cost of a heart failure disease management (HFDM) program delivered within a diverse provider network as demonstrated in the SPAN-CHF randomized controlled trial...
  49. ncbi request reprint Comparison of survival and other complications after heart transplantation in patients taking amiodarone before surgery versus those not taking amiodarone
    Patrick J Blomberg
    Division of Cardiology, Tufts University Medical School, Tufts New England Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 93:379-81. 2004
    ..These findings raise further concern about the use of amiodarone treatment in patients with heart failure before undergoing HT...
  50. ncbi request reprint The problem of decompensated heart failure: nomenclature, classification, and risk stratification
    G Michael Felker
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 145:S18-25. 2003
    ..It also defines the current understanding of strategies for risk stratification in the setting of decompensated heart failure...
  51. ncbi request reprint Rationale, design, and methods for a pivotal randomized clinical trial of continuous aortic flow augmentation in patients with exacerbation of heart failure: the MOMENTUM trial
    Barry Greenberg
    University of California, San Diego, San Diego, California, USA
    J Card Fail 13:715-21. 2007
    ..5 L/min) with an extracorporeal, magnetic, centrifugal pump, improves hemodynamics and renal function with benefits persisting 24 hours after discontinuation...
  52. ncbi request reprint Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)
    Milton Packer
    Division of Circulatory Physiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Circulation 106:920-6. 2002
    ..Combined inhibition of the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may produce greater benefits in heart failure than ACE inhibition alone...
  53. ncbi request reprint Matters of the heart: assessing the cardiovascular safety of new drugs
    Marvin A Konstam
    Am Heart J 146:561-2. 2003
  54. ncbi request reprint Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
    Robert S Bresalier
    Department of Gastrointestinal Medicine and Nutrition, University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    N Engl J Med 352:1092-102. 2005
    ....
  55. ncbi request reprint Ventricular remodeling in heart failure: a credible surrogate endpoint
    Marvin A Konstam
    J Card Fail 9:350-3. 2003
  56. ncbi request reprint Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial
    Inder Anand
    Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN, USA
    Lancet 364:347-54. 2004
    ..We aimed to measure the effects of long-term endothelin-blockade on left-ventricular (LV) remodelling and clinical outcomes in patients with chronic heart failure...
  57. ncbi request reprint Highlights of the 2004 scientific sessions of the Heart Failure Society of America, Toronto, Canada, September 12 to 15, 2004
    Peter Liu
    Heart and Stroke Richard Lewar Centre of Excellence, University of Toronto, and Division of Cardiology, Toronto General Hospital, University Health Network, Toronto, Canada
    J Am Coll Cardiol 45:617-25. 2005
    ..The meeting integrates the best of basic advances with clinical trials and outcomes observations in a single seamless forum. The meeting in Toronto, Canada, attracted close to 3,000 attendees...
  58. ncbi request reprint Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure
    Marvin A Konstam
    Am J Cardiol 96:867-71. 2005
    ..It is therefore appropriate to consider ventricular remodeling in conjunction with outcome events in the construct of clinical trials in HF...
  59. ncbi request reprint Key issues in end point selection for heart failure trials: composite end points
    James D Neaton
    Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota 55414, USA
    J Card Fail 11:567-75. 2005
    ..The aim of this article is to discuss the advantages and disadvantages of composite outcomes and recommend guidelines for reporting them. Examples are used to illustrate key points...
  60. ncbi request reprint Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia
    Mihai Gheorghiade
    Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 97:1064-7. 2006
    ..No differences in adverse events were observed between the groups. In conclusion, tolvaptan appears to be more effective than fluid restriction at correcting hyponatremia in hospitalized subjects, without an increase in adverse events...
  61. ncbi request reprint "Systolic and diastolic dysfunction" in heart failure? Time for a new paradigm
    Marvin A Konstam
    J Card Fail 9:1-3. 2003
  62. ncbi request reprint Percutaneous continuous aortic flow augmentation for cardiac recovery in a chronic heart failure patient with peripheral vascular disease
    Amir Saberin
    Centre Hospitalier de Luxembourg, Luxembourg City, Grand Duchy of Luxembourg
    Congest Heart Fail 12:343-6. 2006
    ..This finding suggests that peripheral vascular disease is a relative-not an absolute-contraindication for CAFA, but requires close monitoring of flow during CAFA therapy...
  63. ncbi request reprint Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction
    Paul A Heidenreich
    11C Cardiology, VA Palo Alto Health Care System, Palo Alto VAMC, 3801 Miranda Avenue, Palo Alto, CA 94034, USA
    J Am Coll Cardiol 43:1019-26. 2004
    ..This study was designed to evaluate the cost-effectiveness of screening patients with a B-type natriuretic peptide (BNP) blood test to identify those with depressed left ventricular systolic function...
  64. ncbi request reprint Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials
    Paul G Shekelle
    Southern California Evidence Based Practice Center, RAND Health, Santa Monica, California 90407 2138, USA
    J Am Coll Cardiol 41:1529-38. 2003
    ....
  65. ncbi request reprint A device is not a drug
    Marvin A Konstam
    J Card Fail 9:155-7. 2003
  66. ncbi request reprint Natriuretic peptides and cardiovascular events: more than a stretch
    Marvin A Konstam
    JAMA 297:212-4. 2007
  67. doi request reprint Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction
    Norman C Wang
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    JAMA 299:2656-66. 2008
    ..Hospitalization for heart failure is associated with high postdischarge mortality and morbidity. The predictive value of the QRS duration during admission for heart failure has not been well studied...
  68. ncbi request reprint Designs for mechanical circulatory support device studies
    James D Neaton
    University of Minnesota School of Public Health, Minneapolis, Minnesota 55415, USA
    J Card Fail 13:63-74. 2007
    ..Because patient availability to evaluate these devices is limited and randomized trials have been slow in enrolling patients, a workshop was convened to consider designs for MCSD development including alternatives to randomized trials...
  69. ncbi request reprint Newer mechanical devices in the management of acute heart failure
    Paul J Mather
    Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA
    Heart Fail Rev 12:167-72. 2007
    ..These new generation devices offer the promise of improved LV function and an enhanced neurohormonal profile for the failing ventricle, thus improving the quality of life in the ever-burgeoning heart failure population...
  70. ncbi request reprint Percutaneous mechanical devices in the management of decompensated heart failure
    Paul J Mather
    Jefferson Heart Institute, 925 Chestnut Street, Mezzanine, Philadelphia, PA 19107, USA
    Curr Heart Fail Rep 4:43-7. 2007
    ..In the coming years, expanded clinical investigation is likely to explore the potential for devices to normalize underlying cardiac function and thereby improve long-term clinical outcomes...